Eric M. Dube - 13 Aug 2021 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role: Chief Executive Officer, Director
Signature: /s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol: TVTX
Transactions as of: 13 Aug 2021
Net transactions value: -$134,142
Form type: 4
Filing time: 17 Aug 2021, 19:40:12 UTC
Previous filing: 03 Jun 2021
Next filing: 06 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TVTX	Common Stock	Award	$0	+17,500	+12%	$0.000000	164,751	13 Aug 2021	Direct	F1
transaction	TVTX	Common Stock	Sale	$134,142	-7,836	-4.8%	$17.12	156,915	17 Aug 2021	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 35,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On August 13, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the PROTECT study.
F2	Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Content

On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 35,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On August 13, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the PROTECT study.

Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.